KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) EBITDA Margin: 2020-2023

Historic EBITDA Margin for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to -516.51%.

  • AbCellera Biologics' EBITDA Margin fell 37463.00% to -516.51% in Q4 2023 from the same period last year, while for Dec 2023 it was -385.86%, marking a year-over-year decrease of 41817.00%. This contributed to the annual value of -574.05% for FY2024, which is 18818.00% down from last year.
  • Latest data reveals that AbCellera Biologics reported EBITDA Margin of -516.51% as of Q4 2023, which was down 20.99% from -426.90% recorded in Q3 2023.
  • AbCellera Biologics' 5-year EBITDA Margin high stood at 57.82% for Q1 2021, and its period low was -516.51% during Q4 2023.
  • Over the past 3 years, AbCellera Biologics' median EBITDA Margin value was -78.56% (recorded in 2022), while the average stood at -164.52%.
  • Per our database at Business Quant, AbCellera Biologics' EBITDA Margin spiked by 44,053bps in 2022 and then slumped by 45,188bps in 2023.
  • AbCellera Biologics' EBITDA Margin (Quarterly) stood at 56.28% in 2020, then plummeted by 1,351bps to 42.76% in 2021, then tumbled by 18,464bps to -141.88% in 2022, then slumped by 37,463bps to -516.51% in 2023.
  • Its last three reported values are -516.51% in Q4 2023, -426.90% for Q3 2023, and -302.37% during Q2 2023.